Skip to search formSkip to main contentSkip to account menu

MK-0366

Known as: MK 366, MK 0366, MK366 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Norfloxacin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1986
1986
The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
The in-vitro activities of four quinolone carboxylic acids against 423 clinical isolates of Gram-negative rods and staphylococci… 
1983
1983
Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715)
Norfloxacin is a new orally absorbed quinoline derivative structurally related to nalidixic acid but showing an expanded… 
1983
1983
Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients.
Norfloxacin (MK-0366) is a new antibacterial agent, closely related to nalidixic acid, with broad spectrum activity against Gram… 
1983
1983
The comparative activity of norfloxacin with other antimicrobial agents against Gram-positive and Gram-negative bacteria.
Norfloxacin (MK0366) displayed appreciable activity against the great majority of Gram-negative and Gram-positive bacteria. The… 
1983
1983
Comparative in vitro activity of norfloxacin against urinary tract pathogens
The in vitro activity of norfloxacin (MK366) against 477 aerobic gram-negative and gram-positive clinical isolates was compared… 
1983
1983
Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strains
We compared the activity of norfloxacin (MK-0366), a new orally absorbable derivative of naladixic acid, with those of other… 
1983
1983
Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.
1983
1983
In vitro activity of norfloxacin in urine compared to that of cinnoxacin, nalidixic acid and pipemidic acid
1. Ito, A., Hirai, K., Inoue, M., Koga, H., Suzue, S., Irikura, T., Mitsuhashi, S.: In vitro antibacterial activity of AM-715, a… 
1983
1983
In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarbo xylic acid (Norfloxacin, MK-0366), a new nalidixic acid… 
Highly Cited
1982
Highly Cited
1982
Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates
The in vitro activity of a new oral antimicrobial agent, norfloxacin (MK-0366), was compared with those of nalidixic acid… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)